First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Approval is based on positive Phase III data from multinational and Japanese studies in patients ...
Please provide your email address to receive an email when new articles are posted on . There is no current treatment for children with APDS aged 4 to 11 years. Diagnostic delays have a mean of 7 ...
Pharming Group NV is a biotechnology firm known for its unique approach to addressing rare and genetic diseases. The company's financials show growth in revenue, primarily driven by strong sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results